Malin Corporation | MLC - Selling And Administration Expenses

Stock Price
7.45
Daily Change
-0.15 -1.97%
Monthly
-6.88%
Yearly
-12.35%
Q2 Forecast
7.23

Malin Corporation reported EUR1.1M in Selling and Administration Expenses for its fiscal semester ending in December of 2024.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
ALKERMES USD 264.59M 77.4M Mar/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Eurofins Scientific SE EUR 0 0 Jun/2023
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Moderna USD 173M 135M Mar/2026
Organon & Co USD 433M 34M Dec/2025
Ovoca Bio EUR 632K 2.33M Jun/2025
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025